Edwards Lifesciences Corporation’s EW first-quarter 2020 adjusted earnings per share (EPS) of $1.51 beat the Zacks Consensus Estimate by 17.1%. Moreover, the figure improved 14.4% year over year.
GAAP EPS was $1.47 in the quarter, marking a massive surge of 24.6% from the year-ago figure of $1.18.
First-quarter net sales improved to $1.13 billion, up 14% over the prior year on both a reported and underlying basis. The metric surpassed the Zacks Consensus Estimate by 7.6%.
Revenues were primarily driven by significant growth in Transcatheter Aortic Valve Replacement (TAVR) sales and strong performance of the Critical Care product line despite challenges arising from the coronavirus outbreak toward the quarter-end.
Edwards Lifesciences Corporation Price, Consensus and EPS Surprise
Edwards Lifesciences Corporation price-consensus-eps-surprise-chart | Edwards Lifesciences Corporation Quote
In the first quarter, sales in the TAVR product group amounted to $742.2 million, up 24.2% from the prior-year figure on reported basis. On an underlying basis, growth was 25.2%.
In the United States, total TAVR procedures rose around 30% year over year. Outside the United States, total TAVR procedures grew in the mid-teens on a year-over-year basis. Global TAVR sales growth through early March was flat with the company's fourth-quarter global growth rate. However, the segment was affected by a fall in procedures resulting from COVID-19 disruptions in the last few weeks of the quarter. However, average selling prices were stable worldwide.
Transcatheter Mitral and Tricuspid Therapies (TMTT) sales totaled $10.5 million, registering strong momentum on increased adoption of the PASCAL mitral valve system in Europe. TMTT sales met the company’s expectations until the latter half of March when there was a sudden decline in sales due to COVID-19.
Surgical Structural Heart’s sales in the quarter totaled $193.4 million, down 9.9% from the year-ago quarter on a reported basis and 9% on an underlying basis. Per management, the downside resulted from lower surgical aortic valve procedures in the United States owing to increased adoption of TAVR. During the latter half of March, there was a sharp decline in procedures related to COVID-19. However, the decline was partly offset by the continued adoption of the INSPIRIS surgical aortic valve.
Critical Care sales totaled $182.6 million in the first quarter, up 3.6% from the year-ago quarter on a reported basis and 0.8% on an underlying basis. The upside was driven by robust demand for the company's disposable pressure monitoring devices used in intensive care units due to the coronavirus pandemic.
In the first quarter, gross profit was $863.6 million, up 13.5%. Although foreign exchange rates had adversely impacted gross profit, the virus outbreak did not have much of an impact.
However, gross margin contracted 14 bps to 76.5%. Favorable impacts from product mix were offset by lower foreign exchange hedge gains and spending in support of the new European Medical Device regulations.
SG&A expenses rose 9.8% year over year to $307.8 million, driven by increased field clinical personnel to support TAVR cases in the United States and TMTT cases in Europe. R&D expenditures escalated 9.3% year over year to $187.4 million on continued investments in TMTT. All these expenses drove operating costs by 9.6% to $495.2 million.
During the reported quarter, operating income was $368.4 million, up 19% from the year-ago quarter’s $309.5 million. Operating margin expanded 147 bps to 32.6%.
Edwards Lifesciences exited the first quarter of 2020 with cash and cash equivalents, and short-term investments of $1.03 billion compared with $1.52 billion at the end of 2019. Long-term debt at the end of first-quarter 2020 was $594.6 million compared with $ 594.4 million at 2019-end.
First-quarter net cash provided by operating activities was $207 million compared with $1.5 million a year ago. Capital expenditure rose to $82.2 million from $42.2 million a year ago.
For 2020, sales are expected in the range of $4-$4.5 billion, down from $4.6-$5 billion announced earlier. The Zacks Consensus Estimate for 2020 revenues is currently pegged at $4.27 billion.
Full-year adjusted EPS is likely to be within $4.75-$5.25, significantly lower than the earlier-announced $6.15-$6.40. The Zacks Consensus Estimate for the same is currently pinned at $4.71.
Given the economic uncertainty prevailing due to the coronavirus impact, Edwards Lifesciences is facing difficulties in predicting the progression of the pandemic and the extent of the disruption to hospital procedures involving the company’s therapies. However, the company expects the pandemic’s impact to be most severe in the second quarter.
Currently, the company projects second-quarter total sales in the range of $700-$900 million. The consensus estimate for the same is currently pegged at $821.7 million.
Edwards Lifesciences exited the first quarter with better-than-expected results despite the adverse impact of the coronavirus outbreak on revenues toward March-end. Globally, TAVR procedures delivered growth, led by strong therapy adoption across all geographies, particularly in the United States. We are upbeat about the rollout of the SAPIEN 3 Ultra and clinician feedback on improved paravalvular leak performance. We are also upbeat about robust sales growth within the Critical Care segment. Moreover, rise in R&D expenses and expansion of the operating margin buoy optimism.
However, the economic doldrums associated with the pandemic caused a drop in TMTT revenues along with dismal performance by the Surgical Structural Heart segment. Also, the gross margin contraction in the first quarter is concerning. Moreover, tough competition in the cardiac devices market and reimbursement issues persist. Given the pandemic-led economic disruption, the company has lowered its 2020 guidance.
Zacks Rank & Key Picks
Edwards Lifesciences currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Chemed Corporation CHE, DexCom DXCM and ViewRay, Inc. VRAY. All the three stocks carry a Zacks Rank #2 (Buy), at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Chemed’s first-quarter 2020 revenues is pegged at $523.6 million, suggesting 13.3% growth from the prior-year reported figure. The same for adjusted earnings per share is anticipated at $3.60, indicating 23.3% improvement from the year-ago reported number.
The Zacks Consensus Estimate for DexCom’s first-quarter 2020 revenues is $356.5 million, implying a 27.1% increase from the year-earlier reported figure. The same for adjusted earnings per share stands at 10 cents, indicating a 300% surge from the year-ago reported figure.
The Zacks Consensus Estimate for ViewRay’s first-quarter 2020 bottom line stands at a loss of 20 cents per share, suggesting a 41.2% improvement from the year-ago quarter.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report
DexCom, Inc. (DXCM) : Free Stock Analysis Report
Chemed Corporation (CHE) : Free Stock Analysis Report
ViewRay, Inc. (VRAY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research